Combination cancer immunotherapy and new immunomodulatory targets (original) (raw)

• Schreiber, R. D., Old, L. J. & Smyth, M. J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331, 1565–1570 (2011).
  CAS PubMed Google Scholar
• Fritsch, E. F. et al. HLA-binding properties of tumor neoepitopes in humans. Cancer Immunol. Res. 2, 522–529 (2014).
  CAS PubMed PubMed Central Google Scholar
• Gubin, M. M. et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515, 577–581 (2014). Identifies tumour-specific mutant proteins (neoantigens) as the major T cell rejection targets following anti-PD1 and/or anti-CTLA4 tumour immunotherapy in mice. Vaccines incorporating these neoantigens can induce tumour rejection.
  CAS PubMed PubMed Central Google Scholar
• Freeman, G. J. et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192, 1027–1034 (2000). Shows that PDL1 is a ligand for PD1 and inhibits T cell activation. It also shows that PDL1 expression is upregulated by IFN γ.
  CAS PubMed PubMed Central Google Scholar
• Blackburn, S. D. et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol. 10, 29–37 (2009). Shows that expression of multiple inhibitory receptors in addition to PD1 is associated with greater T cell exhaustion in a chronic viral infection model.
  CAS PubMed Google Scholar
• Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010). A report of the Phase III trial showing a survival advantage with CTLA4-specific mAb treatment in advanced melanoma; the results supported FDA approval of the first immune checkpoint inhibitor.
  CAS PubMed PubMed Central Google Scholar
• Powles, T. et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515, 558–562 (2014). Although not the first published report of efficacy of therapeutically targeting PDL1, this study demonstrates a 43% response rate in metastatic bladder cancer, a good safety profile and a threefold increase in response rates in tumours that express PDL1 on the tumour-infiltrating immune cells.
  CAS PubMed Google Scholar
• Hamid, O. et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369, 134–144 (2013).
  CAS PubMed PubMed Central Google Scholar
• Brahmer, J. R. et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28, 3167–3175 (2010). This first-in-human trial of a PD1 blocker shows that the therapy is well tolerated and produces a partial response in a patient with melanoma and in a patient with renal cell carcinoma, and a complete response in a patient with colon adenocarcinoma.
  CAS PubMed PubMed Central Google Scholar
• Herbst, R. S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563–567 (2014).
  CAS PubMed PubMed Central Google Scholar
• Garon, E. B. et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372, 2018–2028 (2015).
  PubMed Google Scholar
• Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. http://dx.doi.org/10.1056/nejmoa1500596 (2015).
• Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. http://dx.doi.org/10.1056/nejmoa1503093 (2015).
• Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. http://dx.doi.org/10.1056/nejmoa1504030 (2015).
• Schadendorf, D. et al. Pooled analysis of long-term survival data from Phase II and Phase III trials of ipilimumab in unresectable or metastatic melanoma. J. Clin. Oncol. 33, 1889–1894 (2015). Pooled data from multiple clinical trials of ipilimumab with follow-up for up to 10 years (4,846 patients) demonstrate that the survival curve begins to plateau in year three, indicating durable ongoing responses.
  CAS PubMed PubMed Central Google Scholar
• Wolchok, J. D. et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122–133 (2013). The first Phase I trial of combined CTLA4 and PD1 blockade demonstrates that this combination is highly effective, but highly toxic.
  CAS PubMed PubMed Central Google Scholar
• Postow, M. A. et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372, 2006–2017 (2015). The first randomized Phase II trial to compare the efficacy and toxicity of combination versus monotherapy with immune checkpoint inhibitors. It reports 61% response rates with nivolumab plus ipilimumab versus 11% with ipilimumab alone; however, 54% of patients on the combination had grade 3 or 4 adverse events.
  PubMed PubMed Central Google Scholar
• Jenkins, M. K. & Schwartz, R. H. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J. Exp. Med. 165, 302–319 (1987).
  CAS PubMed Google Scholar
• Suntharalingam, G. et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355, 1018–1028 (2006).
  CAS PubMed Google Scholar
• Antonia, S. J. et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: interim phase I results. J. Clin. Oncol. 32 (Suppl.), 8023 (2014).
  Google Scholar
• Antonia, S. J. et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. 32 (Suppl.), 8113 (2014).
  Google Scholar
• Amin, A. et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. 32 (Suppl.), 5010 (2014).
  Google Scholar
• Hammers, H. et al. Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. 32 (Suppl.), 4504 (2014).
  Google Scholar
• Hamid, O. S. et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM). J. Clin. Oncol. 31 (Suppl.), 9010 (2013).
  Google Scholar
• Postow, M. A. et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med. 366, 925–931 (2012).
  CAS PubMed PubMed Central Google Scholar
• Antonia, S. et al. Phase Ib study of MEDI4736, a programmed cell death ligand-1 (PD-L1) antibody, in combination with tremelimumab, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, in patients (pts) with advanced NSCLC. J. Clin. Oncol. 33 (Suppl.), 3014 (2015).
  Google Scholar
• Parry, R. V. et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol. Cell. Biol. 25, 9543–9553 (2005).
  CAS PubMed PubMed Central Google Scholar
• Korman, A. et al. Activity of anti-PD-1 in murine tumor models: role of “host” PD-L1 and synergistic effect of anti-PD-1 and anti-CTLA-4. J. Immunol. 178 (Suppl.), S82 (2007). First report to demonstrate the synergistic effect of blocking both PD1 and CTLA4 in mouse tumour models; the results formed the basis of the development of this combination in patients.
  Google Scholar
• Freeman, G. J. & Sharpe, A. H. A new therapeutic strategy for malaria: targeting T cell exhaustion. Nat. Immunol. 13, 113–115 (2012).
  CAS PubMed PubMed Central Google Scholar
• Robert, C. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372, 320–330 (2015).
  CAS PubMed Google Scholar
• Dovedi, S. J. et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res. 74, 5458–5468 (2014).
  CAS PubMed Google Scholar
• Keir, M. E., Butte, M. J., Freeman, G. J. & Sharpe, A. H. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26, 677–704 (2008).
  CAS PubMed Google Scholar
• Postow, M. A. et al. Pharmacodynamic effect of ipilimumab on absolute lymphocyte count (ALC) and association with overall survival in patients with advanced melanoma. J. Clin. Oncol. 31 (Suppl.), 9052 (2013).
  Google Scholar
• Le, D. T. & Jaffee, E. M. Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective. Cancer Res. 72, 3439–3444 (2012).
  CAS PubMed PubMed Central Google Scholar
• Vincent, J. et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 70, 3052–3061 (2010).
  CAS PubMed Google Scholar
• Sevko, A. et al. Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model. J. Immunol. 190, 2464–2471 (2013).
  CAS PubMed Google Scholar
• Hannani, D. et al. Prerequisites for the antitumor vaccine-like effect of chemotherapy and radiotherapy. Cancer J. 17, 351–358 (2011).
  CAS PubMed Google Scholar
• Kim, K. et al. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc. Natl Acad. Sci. USA 111, 11774–11779 (2014).
  CAS PubMed PubMed Central Google Scholar
• Papa, M. Z., Vetto, J. T., Ettinghausen, S. E., Mule, J. J. & Rosenberg, S. A. Effect of corticosteroid on the antitumor activity of lymphokine-activated killer cells and interleukin 2 in mice. Cancer Res. 46, 5618–5623 (1986).
  CAS PubMed Google Scholar
• Mier, J. W. et al. Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effects. Blood 76, 1933–1940 (1990).
  CAS PubMed Google Scholar
• Vetto, J. T., Papa, M. Z., Lotze, M. T., Chang, A. E. & Rosenberg, S. A. Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids. J. Clin. Oncol. 5, 496–503 (1987).
  CAS PubMed Google Scholar
• Wolchok, J. et al. Efficacy and safety results from a Phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067). J. Clin. Oncol. 33 (Suppl.), LBA1 (2015).
  Google Scholar
• Donia, M. et al. BRAF inhibition improves tumor recognition by the immune system: potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer. Oncoimmunology 1, 1476–1483 (2012).
  PubMed PubMed Central Google Scholar
• Frederick, D. T. et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin. Cancer Res. 19, 1225–1231 (2013).
  CAS PubMed PubMed Central Google Scholar
• Jiang, X., Zhou, J., Giobbie-Hurder, A., Wargo, J. & Hodi, F. S. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Clin. Cancer Res. 19, 598–609 (2013).
  CAS PubMed Google Scholar
• Cooper, Z. A. et al. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol. Res. 2, 643–654 (2014).
  CAS PubMed PubMed Central Google Scholar
• Ribas, A., Hodi, F. S., Callahan, M., Konto, C. & Wolchok, J. Hepatotoxicity with combination of vemurafenib and ipilimumab. N. Engl. J. Med. 368, 1365–1366 (2013).
  CAS PubMed Google Scholar
• Ribas, A. et al. Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma. J. Clin. Oncol. 33 (Suppl.), 3003 (2015).
  Google Scholar
• Talmadge, J. E. & Gabrilovich, D. I. History of myeloid-derived suppressor cells. Nat. Rev. Cancer 13, 739–752 (2013).
  CAS PubMed PubMed Central Google Scholar
• Finke, J. et al. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int. Immunopharmacol. 11, 856–861 (2011).
  CAS PubMed Google Scholar
• Bhatt, R. S. et al. Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling. Mol. Cancer Ther. 9, 2793–2802 (2010).
  CAS PubMed PubMed Central Google Scholar
• Salven, P., Orpana, A., Teerenhovi, L. & Joensuu, H. Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients. Blood 96, 3712–3718 (2000).
  CAS PubMed Google Scholar
• Zhan, P., Qian, Q. & Yu, L. K. Serum VEGF level is associated with the outcome of patients with hepatocellular carcinoma: a meta-analysis. Hepatobiliary Surg. Nutr. 2, 209–215 (2013).
  PubMed PubMed Central Google Scholar
• Yuan, J. et al. Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab. Cancer Immunol. Res. 2, 127–132 (2014).
  CAS PubMed Google Scholar
• Ohm, J. E. & Carbone, D. P. VEGF as a mediator of tumor-associated immunodeficiency. Immunol. Res. 23, 263–272 (2001).
  CAS PubMed Google Scholar
• Gabrilovich, D. I., Ishida, T., Nadaf, S., Ohm, J. E. & Carbone, D. P. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin. Cancer Res. 5, 2963–2970 (1999).
  CAS PubMed Google Scholar
• Lieu, C. et al. Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and/or chemotherapy (chemo) in patients (pts) with locally advanced or metastatic solid tumors. Ann. Oncol. 25 (Suppl. 4): iv361–iv372 (2014). This is the first report of the combination of a PDL1-specific mAb and a VEGF-specific mAb (bevacizumab) in patients, which was highly tolerable in patients.
  Google Scholar
• Ellis, L. M. The role of neuropilins in cancer. Mol. Cancer Ther. 5, 1099–1107 (2006).
  CAS PubMed Google Scholar
• Chaudhary, B., Khaled, Y. S., Ammori, B. J. & Elkord, E. Neuropilin 1: function and therapeutic potential in cancer. Cancer Immunol. Immunother. 63, 81–99 (2014).
  CAS PubMed Google Scholar
• Papatriantafyllou, M. T cells: neuropilin 1 — distinguishing TReg cell subsets. Nat. Rev. Immunol. 12, 746 (2012).
  CAS PubMed Google Scholar
• Grandclement, C. & Borg, C. Neuropilins: a new target for cancer therapy. Cancers (Basel) 3, 1899–1928 (2011).
  CAS Google Scholar
• Weekes, C. D. et al. A Phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors. Invest. New Drugs 32, 653–660 (2014).
  CAS PubMed Google Scholar
• Patnaik, A. et al. Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 73, 951–960 (2014).
  CAS PubMed Google Scholar
• Delgoffe, G. M. et al. Stability and function of regulatory T cells is maintained by a neuropilin-1-semaphorin-4a axis. Nature 501, 252–256 (2013).
  CAS PubMed PubMed Central Google Scholar
• Vilcek, J. & Feldmann, M. Historical review: cytokines as therapeutics and targets of therapeutics. Trends Pharmacol. Sci. 25, 201–209 (2004).
  CAS PubMed Google Scholar
• Schaer, D. A., Hirschhorn-Cymerman, D. & Wolchok, J. D. Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy. J. Immunother. Cancer 2, 7 (2014).
  PubMed PubMed Central Google Scholar
• Kwon, B. S. et al. Immune responses in 4-1BB (CD137)-deficient mice. J. Immunol. 168, 5483–5490 (2002).
  CAS PubMed Google Scholar
• Chester, C. et al. Biomarker characterization using mass cytometry in a phase 1 trial of urelumab (BMS-663513) in subjects with advanced solid tumors and relapsed/refractory B-cell non-Hodgkin lymphoma. J. Clin. Oncol. 32 (Suppl.), 3017 (2014).
  Google Scholar
• Hwu, W. Targeted therapy for metastatic melanoma: from bench to bedside. HemOnc Today [online], (2010).
• Segal, N. H. et al. A phase 1 study of PF-05082566 (anti-4-1BB) in patients with advanced cancer. J. Clin. Oncol. 32 (Suppl.), 3007 (2014).
  Google Scholar
• Gopal, A. et al. A phase I study of PF-05082566 (anti-4-1BB) + rituximab in patients with CD20+ NHL. J. Clin. Oncol. 33 (Suppl.), 3004 (2015).
  Google Scholar
• Kohrt, H. E. et al. Targeting CD137 enhances the efficacy of cetuximab. J. Clin. Invest. 124, 2668–2682 (2014).
  CAS PubMed PubMed Central Google Scholar
• Ye, Q. et al. CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. Clin. Cancer Res. 20, 44–55 (2014). Demonstrates that in the tumour microenvironment, tumour-reactive T cells express the TNFR 4-1BB, thus bolstering the hypothesis that 4-1BB-specific agonist antibodies will have a synergistic effect with other immune checkpoint therapeutics.
  CAS PubMed Google Scholar
• Bulliard, Y. et al. OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy. Immunol. Cell Biol. 92, 475–480 (2014).
  CAS PubMed Google Scholar
• Guo, Z. et al. PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer. PLoS ONE 9, e89350 (2014).
  PubMed PubMed Central Google Scholar
• Guo, Z. et al. Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer. J. Transl. Med. 11, 215 (2013).
  PubMed PubMed Central Google Scholar
• Adler, A. J. & Vella, A. T. Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation. Oncoimmunology 2, e22837 (2013).
  PubMed PubMed Central Google Scholar
• Wei, H. et al. Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin. PLoS ONE 8, e84927 (2013).
  PubMed PubMed Central Google Scholar
• Kovacsovics-Bankowski, M. et al. Phase I/II clinical trial of anti-OX40, radiation and cyclophosphamide in patients with prostate cancer: immunological analysis. J. Immunother. Cancer 1, 255 (2013).
  Google Scholar
• Curti, B. D. et al. OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res. 73, 7189–7198 (2013).
  CAS PubMed PubMed Central Google Scholar
• Cohen, A. D. et al. Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. PLoS ONE 5, e10436 (2010).
  PubMed PubMed Central Google Scholar
• Lu, L. et al. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs. J. Transl. Med. 12, 36 (2014).
  PubMed PubMed Central Google Scholar
• Grewal, I. S. CD70 as a therapeutic target in human malignancies. Expert Opin. Ther. Targets 12, 341–351 (2008).
  CAS PubMed Google Scholar
• Ansell, S. M. et al. Phase I evaluation of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies. J. Clin. Oncol. 32 (Suppl.), 3034 (2014).
  Google Scholar
• Infante, J. R. et al. Immunologic activity of an activating anti-CD27 antibody (CDX-1127) in patients (pts) with solid tumors. J. Clin. Oncol. 32 (Suppl.), 3027 (2014).
  Google Scholar
• Twohig, J. P. et al. The death receptor 3/TL1A pathway is essential for efficient development of antiviral CD4+ and CD8+ T-cell immunity. FASEB J. 26, 3575–3586 (2012).
  CAS PubMed Google Scholar
• Bossen, C. et al. Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human. J. Biol. Chem. 281, 13964–13971 (2006).
  CAS PubMed Google Scholar
• Meylan, F. et al. The TNF-family receptor DR3 is essential for diverse T cell-mediated inflammatory diseases. Immunity 29, 79–89 (2008).
  CAS PubMed PubMed Central Google Scholar
• Slebioda, T. J. et al. Triggering of TNFRSF25 promotes CD8+ T-cell responses and anti-tumor immunity. Eur. J. Immunol. 41, 2606–2611 (2011).
  CAS PubMed Google Scholar
• Schreiber, T. H. & Podack, E. R. Immunobiology of TNFSF15 and TNFRSF25. Immunol. Res. 57, 3–11 (2013).
  CAS PubMed Google Scholar
• Schreiber, T. H., Wolf, D., Bodero, M., Gonzalez, L. & Podack, E. R. T cell costimulation by TNFR superfamily (TNFRSF)4 and TNFRSF25 in the context of vaccination. J. Immunol. 189, 3311–3318 (2012).
  CAS PubMed Google Scholar
• Bodmer, J. L., Schneider, P. & Tschopp, J. The molecular architecture of the TNF superfamily. Trends Biochem. Sci. 27, 19–26 (2002).
  CAS PubMed Google Scholar
• Bajor, D. et al. Combination of agonistic CD40 monoclonal antibody CP-870,893 and anti-CTLA-4 antibody tremelimumab in patients with metastatic melanoma. American Association for Cancer Research Annual Meeting [online], (2015).
  Google Scholar
• Zippelius, A., Schreiner, J., Herzig, P. & Muller, P. Induced PD-L1 expression mediates acquired resistance to agonistic anti-CD40 treatment. Cancer Immunol. Res. 3, 236–244 (2015).
  CAS PubMed Google Scholar
• Medina-Echeverz, J. et al. Systemic agonistic anti-CD40 treatment of tumor-bearing mice modulates hepatic myeloid-suppressive cells and causes immune-mediated liver damage. Cancer Immunol. Res. 3, 557–566 (2015).
  CAS PubMed PubMed Central Google Scholar
• Cai, G. et al. CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator. Nat. Immunol. 9, 176–185 (2008).
  CAS PubMed Google Scholar
• Derre, L. et al. BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. J. Clin. Invest. 120, 157–167 (2010).
  CAS PubMed Google Scholar
• Pasero, C. & Olive, D. Interfering with coinhibitory molecules: BTLA/HVEM as new targets to enhance anti-tumor immunity. Immunol. Lett. 151, 71–75 (2013).
  CAS PubMed Google Scholar
• Watanabe, N. et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat. Immunol. 4, 670–679 (2003).
  CAS PubMed Google Scholar
• Huang, C. T. et al. Role of LAG-3 in regulatory T cells. Immunity 21, 503–513 (2004).
  CAS PubMed Google Scholar
• Woo, S. R. et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 72, 917–927 (2012). The combination of LAG3 and PD1 blockade in a mouse tumour model is more effective than either alone, prompting the development of this combination in an ongoing clinical trial.
  CAS PubMed Google Scholar
• Matsuzaki, J. et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc. Natl Acad. Sci. USA 107, 7875–7880 (2010).
  CAS PubMed PubMed Central Google Scholar
• Wang-Gillam, A. et al. A Phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma. Invest. New Drugs 31, 707–713 (2013).
  CAS PubMed Google Scholar
• Brignone, C. et al. First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity. J. Transl. Med. 8, 71 (2010).
  PubMed PubMed Central Google Scholar
• Brignone, C., Escudier, B., Grygar, C., Marcu, M. & Triebel, F. A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma. Clin. Cancer Res. 15, 6225–6231 (2009).
  CAS PubMed Google Scholar
• McIntire, J. J. et al. Identification of Tapr (an airway hyperreactivity regulatory locus) and the linked Tim gene family. Nat. Immunol. 2, 1109–1116 (2001).
  CAS PubMed Google Scholar
• Freeman, G. J., Casasnovas, J. M., Umetsu, D. T. & DeKruyff, R. H. TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity. Immunol. Rev. 235, 172–189 (2010).
  CAS PubMed PubMed Central Google Scholar
• Jin, H. T. et al. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc. Natl Acad. Sci. USA 107, 14733–14738 (2010).
  CAS PubMed PubMed Central Google Scholar
• Sakuishi, K. et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 207, 2187–2194 (2010). Promising results from the combination of TIM3 and PD1 blockade in mouse tumours support the development of this combination in patients.
  CAS PubMed PubMed Central Google Scholar
• Zhu, C. et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat. Immunol. 6, 1245–1252 (2005).
  CAS PubMed Google Scholar
• Huang, Y. H. et al. CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature 517, 386–390 (2015).
  CAS PubMed Google Scholar
• DeKruyff, R. H. et al. T cell/transmembrane, Ig, and mucin-3 allelic variants differentially recognize phosphatidylserine and mediate phagocytosis of apoptotic cells. J. Immunol. 184, 1918–1930 (2010).
  CAS PubMed Google Scholar
• Sakuishi, K., Jayaraman, P., Behar, S. M., Anderson, A. C. & Kuchroo, V. K. Emerging Tim-3 functions in antimicrobial and tumor immunity. Trends Immunol. 32, 345–349 (2011).
  CAS PubMed PubMed Central Google Scholar
• Madireddi, S. et al. Galectin-9 controls the therapeutic activity of 4-1BB-targeting antibodies. J. Exp. Med. 211, 1433–1448 (2014).
  CAS PubMed PubMed Central Google Scholar
• Gleason, M. K. et al. Tim-3 is an inducible human natural killer cell receptor that enhances interferon γ production in response to galectin-9. Blood 119, 3064–3072 (2012).
  CAS PubMed PubMed Central Google Scholar
• Pillai, S., Netravali, I. A., Cariappa, A. & Mattoo, H. Siglecs and immune regulation. Annu. Rev. Immunol. 30, 357–392 (2012).
  CAS PubMed PubMed Central Google Scholar
• Jandus, C. et al. Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance. J. Clin. Invest. 124, 1810–1820 (2014).
  CAS PubMed PubMed Central Google Scholar
• Laubli, H. et al. Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer. Proc. Natl Acad. Sci. USA 111, 14211–14216 (2014).
  CAS PubMed PubMed Central Google Scholar
• Takamiya, R., Ohtsubo, K., Takamatsu, S., Taniguchi, N. & Angata, T. The interaction between Siglec-15 and tumor-associated sialyl-Tn antigen enhances TGF-β secretion from monocytes/macrophages through the DAP12-Syk pathway. Glycobiology 23, 178–187 (2013).
  CAS PubMed Google Scholar
• Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252–264 (2012).
  CAS PubMed PubMed Central Google Scholar
• Chen, L. & Flies, D. B. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat. Rev. Immunol. 13, 227–242 (2013).
  PubMed PubMed Central Google Scholar
• Zhao, R. et al. HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function. Proc. Natl Acad. Sci. USA 110, 9879–9884 (2013).
  CAS PubMed PubMed Central Google Scholar
• Sharpe, A. H. Mechanisms of costimulation. Immunol. Rev. 229, 5–11 (2009).
  CAS PubMed PubMed Central Google Scholar
• Capece, D., Verzella, D., Fischietti, M., Zazzeroni, F. & Alesse, E. Targeting costimulatory molecules to improve antitumor immunity. J. Biomed. Biotechnol. 2012, 926321 (2012).
  PubMed PubMed Central Google Scholar
• Ng Tang, D. et al. Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Cancer Immunol. Res. 1, 229–234 (2013).
  PubMed Google Scholar
• Fan, X., Quezada, S. A., Sepulveda, M. A., Sharma, P. & Allison, J. P. Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy. J. Exp. Med. 211, 715–725 (2014).
  CAS PubMed PubMed Central Google Scholar
• Yap, E. H., Rosche, T., Almo, S. & Fiser, A. Functional clustering of immunoglobulin superfamily proteins with protein–protein interaction information calibrated hidden Markov model sequence profiles. J. Mol. Biol. 426, 945–961 (2014).
  CAS PubMed Google Scholar
• Le Mercier, I. et al. VISTA regulates the development of protective antitumor immunity. Cancer Res. 74, 1933–1944 (2014).
  CAS PubMed Google Scholar
• Janakiram, M. et al. Expression, clinical significance, and receptor identification of the newest B7 family member HHLA2 protein. Clin. Cancer Res. 21, 2359–2366 (2015).
  CAS PubMed Google Scholar
• Zhu, Y. et al. B7-H5 costimulates human T cells via CD28H. Nat. Commun. 4, 2043 (2013).
  PubMed Google Scholar
• Nguyen, T., Liu, X. K., Zhang, Y. & Dong, C. BTNL2, a butyrophilin-like molecule that functions to inhibit T cell activation. J. Immunol. 176, 7354–7360 (2006).
  CAS PubMed Google Scholar
• Valentonyte, R. et al. Sarcoidosis is associated with a truncating splice site mutation in BTNL2. Nat. Genet. 37, 357–364 (2005).
  CAS PubMed Google Scholar
• Arnett, H. A. & Viney, J. L. Immune modulation by butyrophilins. Nat. Rev. Immunol. 14, 559–569 (2014).
  CAS PubMed Google Scholar
• Fitzgerald, L. M. et al. Germline missense variants in the BTNL2 gene are associated with prostate cancer susceptibility. Cancer Epidemiol. Biomarkers Prev. 22, 1520–1528 (2013).
  CAS PubMed PubMed Central Google Scholar
• Vijai, J. et al. A genome-wide association study suggests evidence of variants at 6p21.32 associated with marginal zone lymphoma. Cancer Res. 74 (Suppl. 19), 5071 (2014).
  Google Scholar
• Abeler-Dorner, L., Swamy, M., Williams, G., Hayday, A. C. & Bas, A. Butyrophilins: an emerging family of immune regulators. Trends Immunol. 33, 34–41 (2012).
  PubMed Google Scholar
• Rubinstein, R., Ramagopal, U. A., Nathenson, S. G., Almo, S. C. & Fiser, A. Functional classification of immune regulatory proteins. Structure 21, 766–776 (2013).
  CAS PubMed PubMed Central Google Scholar
• de Andrade, L. F., Smyth, M. J. & Martinet, L. DNAM-1 control of natural killer cells functions through nectin and nectin-like proteins. Immunol. Cell Biol. 92, 237–244 (2014).
  PubMed Google Scholar
• Sema Kurtulus, S. et al. Mechanisms of TIGIT-driven immune suppression in cancer. J. Immunother. Cancer 2 (Suppl. 3), O13 (2014).
  PubMed Central Google Scholar
• Chauvin, J. M. et al. TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients. J. Clin. Invest. 125, 2046–2058 (2015).
  PubMed PubMed Central Google Scholar
• Johnston, R. J. et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8+ T cell effector function. Cancer Cell 26, 923–937 (2014). TIGIT is identified as an inhibitory receptor mediating exhaustion on CD8+ T cells; the combination of TIGIT and PDL1 blockade is more effective than either alone in preclinical models.
  CAS PubMed Google Scholar
• Guillerey, C. et al. Immunosurveillance and therapy of multiple myeloma are CD226 dependent. J. Clin. Invest. 125, 2077–2089 (2015).
  PubMed PubMed Central Google Scholar
• Li, A. H. et al. Analysis of loss-of-function variants and 20 risk factor phenotypes in 8,554 individuals identifies loci influencing chronic disease. Nat. Genet. 47, 640–642 (2015).
  CAS PubMed PubMed Central Google Scholar
• Beano, A. et al. Correlation between NK function and response to trastuzumab in metastatic breast cancer patients. J. Transl. Med. 6, 25 (2008). Elucidates the critical role of natural killer cells in mediating the activity of trastuzumab in patients with breast cancer.
  PubMed PubMed Central Google Scholar
• Vey, N. et al. A Phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. Blood 120, 4317–4323 (2012).
  CAS PubMed Google Scholar
• Raulet, D. H. Roles of the NKG2D immunoreceptor and its ligands. Nat. Rev. Immunol. 3, 781–790 (2003).
  CAS PubMed Google Scholar
• Spear, P., Wu, M. R., Sentman, M. L. & Sentman, C. L. NKG2D ligands as therapeutic targets. Cancer Immun. 13, 8 (2013).
  PubMed PubMed Central Google Scholar
• Farnault, L., Sanchez, C., Baier, C., Le Treut, T. & Costello, R. T. Hematological malignancies escape from NK cell innate immune surveillance: mechanisms and therapeutic implications. Clin. Dev. Immunol. 2012, 421702 (2012).
  PubMed PubMed Central Google Scholar
• Bonnafous, C. et al. Targeting MICA with therapeutic antibodies for the treatment of cancer (Poster). J. Immunother. Cancer 1 (Suppl. 1), P41 (2013).
  PubMed Central Google Scholar
• Wada, H., Matsumoto, N., Maenaka, K., Suzuki, K. & Yamamoto, K. The inhibitory NK cell receptor CD94/NKG2A and the activating receptor CD94/NKG2C bind the top of HLA-E through mostly shared but partly distinct sets of HLA-E residues. Eur. J. Immunol. 34, 81–90 (2004).
  CAS PubMed Google Scholar
• Chretien, A. S. et al. Cancer-induced alterations of NK-mediated target recognition: current and investigational pharmacological strategies aiming at restoring NK-mediated anti-tumor activity. Front. Immunol. 5, 122 (2014).
  PubMed PubMed Central Google Scholar
• Sheu, J. & Shih, le-M. HLA-G and immune evasion in cancer cells. J. Formos Med. Assoc. 109, 248–257 (2010).
  CAS PubMed Google Scholar
• Alegre, E. et al. Some basic aspects of HLA-G biology. J. Immunol. Res. 2014, 657625 (2014).
  PubMed PubMed Central Google Scholar
• González, A. et al. The immunosuppressive molecule HLA-G and its clinical implications. Crit. Rev. Clin. Lab Sci. 49, 63–84 (2012).
  PubMed Google Scholar
• Stark, S. & Watzl, C. 2B4 (CD244), NTB-A and CRACC (CS1) stimulate cytotoxicity but no proliferation in human NK cells. Int. Immunol. 18, 241–247 (2006).
  CAS PubMed Google Scholar
• Valiante, N. M. & Trinchieri, G. Identification of a novel signal transduction surface molecule on human cytotoxic lymphocytes. J. Exp. Med. 178, 1397–1406 (1993).
  CAS PubMed Google Scholar
• Ljunggren, H. G. & Malmberg, K. J. Prospects for the use of NK cells in immunotherapy of human cancer. Nat. Rev. Immunol. 7, 329–339 (2007).
  CAS PubMed Google Scholar
• Munn, D. H. Blocking IDO activity to enhance anti-tumor immunity. Front. Biosci. (Elite Ed) 4, 734–745 (2012). This review highlights immune suppression mediated by IDO in both the tumour and its draining lymph nodes.
  Google Scholar
• Gibney, G. T. et al. Preliminary results from a phase 1/2 study of INCB024360 combined with ipilimumab (ipi) in patients (pts) with melanoma. J. Clin. Oncol. 32 (Suppl.), 3010 (2014).
  Google Scholar
• Soliman, H. H. et al. A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors. Oncotarget 5, 8136–8146 (2014).
  PubMed PubMed Central Google Scholar
• [No authors listed.] NewLink Genetics announces exclusive worldwide licensing agreement for development of NLG919, an IDO inhibitor in Phase 1, and research collaboration for the discovery of next generation IDO/TDO inhibitors. NewLink Genetics [online], (2014).
• [No authors listed.] Bristol-Myers Squibb to expand its immuno-oncology pipeline with agreement to acquire Flexus Biosciences, Inc. Bristol-Myers Squibb [online], (2015).
• Margadant, C. & Sonnenberg, A. Integrin-TGF-β crosstalk in fibrosis, cancer and wound healing. EMBO Rep. 11, 97–105 (2010).
  CAS PubMed PubMed Central Google Scholar
• Gueorguieva, I. et al. Defining a therapeutic window for the novel TGF-β inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model. Br. J. Clin. Pharmacol. 77, 796–807 (2014).
  CAS PubMed PubMed Central Google Scholar
• Bhola, N. E. et al. TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer. J. Clin. Invest. 123, 1348–1358 (2013). Shows that TGFß-dependent signals underlie resistance to chemotherapy via multiple mechanisms, including blunting the antitumour immune response.
  CAS PubMed PubMed Central Google Scholar
• Bedi, A. et al. Inhibition of TGF-β enhances the in vivo antitumor efficacy of EGF receptor-targeted therapy. Mol. Cancer Ther. 11, 2429–2439 (2012).
  CAS PubMed PubMed Central Google Scholar
• Hanks, B. A., Holtzhausen, A., Evans, K., Heid, M. & Blobe, G. C. Combinatorial TGF-β signaling blockade and anti-CTLA-4 antibody immunotherapy in a murine BRAFV600E-PTEN−/− transgenic model of melanoma. J. Clin. Oncol. 32 (Suppl.), 3011 (2014).
  Google Scholar
• Wilson, W. R. & Hay, M. P. Targeting hypoxia in cancer therapy. Nat. Rev. Cancer 11, 393–410 (2011).
  CAS PubMed Google Scholar
• Ohta, A. et al. A2A adenosine receptor protects tumors from antitumor T cells. Proc. Natl Acad. Sci. USA 103, 13132–13137 (2006).
  CAS PubMed PubMed Central Google Scholar
• Cekic, C. & Linden, J. Adenosine A2A receptors intrinsically regulate CD8+ T cells in the tumor microenvironment. Cancer Res. 74, 7239–7249 (2014).
  CAS PubMed PubMed Central Google Scholar
• Jones, G. B. & Yuan, G. Towards next generation adenosine A2A receptor antagonists. Curr. Med. Chem. 21, 3918–3935 (2014).
  PubMed Google Scholar
• Yegutkin, G. G. Nucleotide- and nucleoside-converting ectoenzymes: important modulators of purinergic signalling cascade. Biochim. Biophys. Acta 1783, 673–694 (2008).
  CAS PubMed Google Scholar
• Mandapathil, M. et al. Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells. J. Biol. Chem. 285, 7176–7186 (2010).
  CAS PubMed Google Scholar
• Iannone, R., Miele, L., Maiolino, P., Pinto, A. & Morello, S. Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model. Am. J. Cancer Res. 4, 172–181 (2014).
  PubMed PubMed Central Google Scholar
• Allard, B., Pommey, S., Smyth, M. J. & Stagg, J. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin. Cancer Res. 19, 5626–5635 (2013). Shows that blocking CD73 improves the effect of both PD1 and CTLA4 blockade, and preferentially synergizes with PD1 blockade because activation of the adenosine receptor enhances PD1 expression.
  CAS PubMed Google Scholar
• Hatfield, S. M. et al. Immunological mechanisms of the antitumor effects of supplemental oxygenation. Sci. Transl. Med. 7, 277ra30 (2015).
  CAS PubMed PubMed Central Google Scholar
• Cekic, C., Day, Y. J., Sag, D. & Linden, J. Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment. Cancer Res. 74, 7250–7259 (2014).
  CAS PubMed PubMed Central Google Scholar
• Morello, S. & Miele, L. Targeting the adenosine A2b receptor in the tumor microenvironment overcomes local immunosuppression by myeloid-derived suppressor cells. OncoImmunology 3, e27989 (2014).
  PubMed PubMed Central Google Scholar
• Hoskin, D. W., Mader, J. S., Furlong, S. J., Conrad, D. M. & Blay, J. Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review). Int. J. Oncol. 32, 527–535 (2008).
  CAS PubMed Google Scholar
• Srivastava, M. K. et al. Myeloid suppressor cell depletion augments antitumor activity in lung cancer. PLoS ONE 7, e40677 (2012).
  CAS PubMed PubMed Central Google Scholar
• Feig, C. et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc. Natl Acad. Sci. USA 110, 20212–20217 (2013).
  CAS PubMed PubMed Central Google Scholar
• Luster, T. A. et al. Plasma protein β-2-glycoprotein 1 mediates interaction between the anti-tumor monoclonal antibody 3G4 and anionic phospholipids on endothelial cells. J. Biol. Chem. 281, 29863–29871 (2006).
  CAS PubMed Google Scholar
• Shtivelband, M. et al. Randomized, blinded, placebo-controlled phase II trial of docetaxel and bavituximab as second-line therapy in locally advanced or metastatic non-squamous non-small cell lung cancer. J. Clin. Oncol. 31 (Suppl.), 8095 (2013).
  Google Scholar
• Yopp, A. et al. Antibody-mediated blockade of phosphatidylserine enhances the antitumor activity of targeted therapy and immune checkpoint inhibitors by affecting myeloid and lymphocyte populations in the tumor microenvironment. J. Immunother. Cancer 2 (Suppl. 3), P266 (2014). Blocking phosphotidylserine, a ligand of the co-inhibitory receptor TIM3, improves the efficacy of PD1 and CTLA4 tumour immunotherapy.
  PubMed Central Google Scholar
• Huang, X. et al. Antibody-mediated phosphatidylserine blockade significantly enhances the efficacy of downstream immune checkpoint inhibition in K1735 mouse melanoma. J. Immunother. Cancer 2 (Suppl. 3), P205 (2014).
  PubMed Central Google Scholar
• Garon, E. B. et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 384, 665–673 (2014).
  CAS PubMed Google Scholar
• Tseng, D. et al. Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proc. Natl Acad. Sci. USA 110, 11103–11108 (2013). Targeting CD47 increases phagocytosis, enhances antitumour responses and synergizes with many antitumour mAbs in vivo.
  CAS PubMed PubMed Central Google Scholar
• Weiskopf, K. et al. Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies. Science 341, 88–91 (2013).
  CAS PubMed Google Scholar
• Jaiswal, S. et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 138, 271–285 (2009).
  CAS PubMed PubMed Central Google Scholar
• Chao, M. P. et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 142, 699–713 (2010).
  CAS PubMed PubMed Central Google Scholar
• Melero, I. et al. Therapeutic vaccines for cancer: an overview of clinical trials. Nat. Rev. Clin. Oncol. 11, 509–524 (2014).
  CAS PubMed Google Scholar
• Taube, J. M. et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci. Transl. Med. 4, 127ra37 (2012). Describes the feedback loop whereby tumours dominantly evade the immune response by expressing PDL1 in response to IFN γ produced by activated T cells at the lymphocyte-rich tumour margin.
  PubMed PubMed Central Google Scholar
• Jass, J. R. Lymphocytic infiltration and survival in rectal cancer. J. Clin. Pathol. 39, 585–589 (1986).
  CAS PubMed PubMed Central Google Scholar
• Sobin, L. & Wittekind, C. TNM Classification of Malignant Tumors 2nd edn (Wiley, 2002).
  Google Scholar
• Mlecnik, B., Bindea, G., Pages, F. & Galon, J. Tumor immunosurveillance in human cancers. Cancer Metastasis Rev. 30, 5–12 (2011).
  CAS PubMed PubMed Central Google Scholar
• Galon, J. et al. Cancer classification using the Immunoscore: a worldwide task force. J. Transl. Med. 10, 205 (2012).
  PubMed PubMed Central Google Scholar
• Angell, H. & Galon, J. From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. Curr. Opin. Immunol. 25, 261–267 (2013).
  CAS PubMed Google Scholar
• Messina, J. L. et al. 12-chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy? Sci. Rep. 2, 765 (2012).
  PubMed PubMed Central Google Scholar
• Thompson, R. H. et al. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc. Natl Acad. Sci. USA 101, 17174–17179 (2004). The first article to show that PDL1 expression on tumour cells and on infiltrating lymphocytes in kidney cancer is associated with worse prognosis and increased cancer-specific death.
  CAS PubMed PubMed Central Google Scholar
• Giraldo, N. A. et al. Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer. Clin. Cancer Res. http://dx.doi.org/10.1158/1078-0432.CCR-14-2926 (2015).
• Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568–571 (2014). Shows that tumours that have high CD8 infiltrate and PDL1 expression on the tumour and at the tumour margin are more likely to respond to PD1 immunotherapy.
  CAS PubMed PubMed Central Google Scholar
• Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J.Med. 365, 725–733 (2011).
  CAS PubMed PubMed Central Google Scholar
• John, L. B. et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin. Cancer Res. 19, 5636–5646 (2013). Shows that chimeric antigen receptor T cells can express PD1, be susceptible to PD1-mediated inhibition of T cell activation, and that PD1 blockade can enhance the activity of chimeric antigen receptor T cells in mouse models.
  CAS PubMed Google Scholar
• Wolchok, J. D. et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15, 7412–7420 (2009).
  CAS PubMed Google Scholar
• Nordlund, J. J. et al. Vitiligo in patients with metastatic melanoma: a good prognostic sign. J. Am. Acad. Dermatol. 9, 689–696 (1983).
  CAS PubMed Google Scholar
• Bystryn, J. C., Rigel, D., Friedman, R. J. & Kopf, A. Prognostic significance of hypopigmentation in malignant melanoma. Arch. Dermatol. 123, 1053–1055 (1987).
  CAS PubMed Google Scholar
• Scalzo, S. et al. Primary hypothyroidism associated with interleukin-2 and interferon α-2 therapy of melanoma and renal carcinoma. Eur. J. Cancer 26, 1152–1156 (1990).
  CAS PubMed Google Scholar
• Becker, J. C., Winkler, B., Klingert, S. & Brocker, E. B. Antiphospholipid syndrome associated with immunotherapy for patients with melanoma. Cancer 73, 1621–1624 (1994).
  CAS PubMed Google Scholar
• Rosenberg, S. A. & White, D. E. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J. Immunother. Emphasis Tumor Immunol. 19, 81–84 (1996).
  CAS PubMed Google Scholar
• Atkins, M. B. et al. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N. Engl. J. Med. 318, 1557–1563 (1988).
  CAS PubMed Google Scholar
• Attia, P. et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol. 23, 6043–6053 (2005).
  CAS PubMed Google Scholar
• Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507–2516 (2011).
  CAS PubMed PubMed Central Google Scholar
• Beck, K. E. et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J. Clin. Oncol. 24, 2283–2289 (2006).
  CAS PubMed Google Scholar
• Kyi, C., Carvajal, R. D., Wolchok, J. D. & Postow, M. A. Ipilimumab in patients with melanoma and autoimmune disease. J. Immunother. Cancer 2, 35 (2014).
  PubMed PubMed Central Google Scholar
• Hurwitz, A. A. et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res. 60, 2444–2448 (2000).
  CAS PubMed Google Scholar
• Hodi, F. S. et al. Ipilimumab plus sargramostim versus ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA 312, 1744–1753 (2014). Treatment with ipilimumab plus sargramostim (a granulocyte–macrophage colony-stimulating factor) versus ipilimumab alone results in lower toxicity and modestly better overall survival.
  CAS PubMed PubMed Central Google Scholar
• Jinushi, M. et al. MFG-E8-mediated uptake of apoptotic cells by APCs links the pro- and antiinflammatory activities of GM-CSF. J. Clin. Invest. 117, 1902–1913 (2007).
  CAS PubMed PubMed Central Google Scholar
• Rini, B. I. et al. Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma. Cancer 117, 758–767 (2011).
  CAS PubMed Google Scholar
• Maker, A. V. et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann. Surg. Oncol. 12, 1005–1016 (2005).
  PubMed PubMed Central Google Scholar
• Robert, C. et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364, 2517–2526 (2011).
  CAS PubMed Google Scholar
• Stewart, R. et al. The role of Fc gamma receptors in the activity of immunomodulatory antibodies for cancer. J. Immunother. Cancer 2, 29 (2014).
  Google Scholar
• Gomez-Roca, C. A. et al. Phase I study of RG7155, a novel anti-CSF1R antibody, in patients with advanced/metastatic solid tumors. J. Clin. Oncol. 33 (Suppl.; abstr.), 3005 (2015).
  Google Scholar
• Simpson, T. R. et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med. 210, 1695–1710 (2013).
  CAS PubMed PubMed Central Google Scholar
• Selby, M. J. et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol. Res. 1, 32–42 (2013). Shows that an ADCC-activating Fc region on the CTLA4-specific mAb is essential for antitumour activity in a mouse tumour model, suggesting that the depletion of CTLA4-positive T Reg cells within the tumour is a major mechanism.
  CAS PubMed Google Scholar
• Mahoney, K. M. & Atkins, M. B. Prognostic and predictive markers for the new immunotherapies. Oncology (Williston Park) 28 (Suppl. 3), 39–48 (2014). An overview of the differences between prognostic and predictive markers as well as the candidate predictive and pharmacodynamic markers in the field of immune checkpoint blockade, focusing on PDL1 expression.
  Google Scholar
• Green, M. R. et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 116, 3268–3277 (2010). This paper shows that genomic amplification of 9p24.1 encoding Janus kinase 2, PDL1 and PDL2 results in PDL1 and PDL2 overexpression in Hodgkin and primary mediastinal lymphomas.
  CAS PubMed PubMed Central Google Scholar
• Ansell, S. M. et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N. Engl. J. Med. 372, 311–319 (2015).
  PubMed Google Scholar
• Taube, J. M. et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer Res. 20, 5064–5074 (2014).
  CAS PubMed PubMed Central Google Scholar
• Paz-Ares, L. et al. Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC). J. Clin. Oncol. 33 (Suppl.), LBA109 (2015).
  Google Scholar
• Brahmer, J. et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1504627 (2015).
• Schellens, J. et al. CEA-targeted engineered IL2: clinical confirmation of tumor targeting and evidence of intra-tumoral immune activation. J. Clin. Oncol. 33 (Suppl.), 3016 (2015).
  Google Scholar
• Sznol, M. & Chen, L. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer-response. Clin. Cancer Res. 19, 5542 (2013).
  CAS PubMed PubMed Central Google Scholar
• Grosso, J. et al. Programmed death-ligand 1 (PD-L1) expression in various tumor types. J. Immunother. Cancer 1 (Suppl 1), P53 (2013).
  PubMed Central Google Scholar
• Brown, J. A. et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J. Immunol. 170, 1257–1266 (2003). Shows that enhanced T cell activation is a consequence of blockade of the interaction with PD1, not signal transduction by PDL1 or PDL2. The paper also presents data on PDL1 expression in a broad range of solid and haematological malignancies and normal tissues.
  CAS PubMed Google Scholar
• Dong, H. et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8, 793–800 (2002). The first paper to show PDL1 expression in situ on solid tumours, including lung, ovary, colon and melanoma.
  CAS PubMed Google Scholar
• Ohigashi, Y. et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin. Cancer Res. 11, 2947–2953 (2005).
  CAS PubMed Google Scholar
• Nomi, T. et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin. Cancer Res. 13, 2151–2157 (2007).
  CAS PubMed Google Scholar
• Hamanishi, J. et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc. Natl Acad. Sci. USA 104, 3360–3365 (2007).
  CAS PubMed PubMed Central Google Scholar
• Gao, Q. et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin. Cancer Res. 15, 971–979 (2009).
  CAS PubMed Google Scholar
• Latchman, Y. et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2, 261–268 (2001). Identifies PDL2 as a second ligand for PD1, recruitment of SHP2 as a mechanism for PD1-mediated inhibition of T cell activation, and first shows PDL1 expression on solid tumour cell lines.
  CAS PubMed Google Scholar
• Shi, M. et al. Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain. Am. J. Surg. Pathol. 38, 1715–1723 (2014).
  PubMed PubMed Central Google Scholar
• Sun, Y. et al. B7-H3 and B7-H4 expression in non-small-cell lung cancer. Lung Cancer 53, 143–151 (2006).
  PubMed Google Scholar
• Wu, C. P. et al. Relationship between co-stimulatory molecule B7-H3 expression and gastric carcinoma histology and prognosis. World J. Gastroenterol. 12, 457–459 (2006).
  CAS PubMed PubMed Central Google Scholar
• Crispen, P. L. et al. Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin. Cancer Res. 14, 5150–5157 (2008).
  CAS PubMed PubMed Central Google Scholar
• Loos, M. et al. Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer. BMC Cancer 9, 463 (2009).
  PubMed PubMed Central Google Scholar
• Sun, J. et al. Clinical significance and regulation of the costimulatory molecule B7-H3 in human colorectal carcinoma. Cancer Immunol. Immunother. 59, 1163–1171 (2010).
  CAS PubMed Google Scholar
• Zang, X. et al. Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Mod. Pathol. 23, 1104–1112 (2010).
  CAS PubMed PubMed Central Google Scholar
• Roth, T. J. et al. B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res. 67, 7893–7900 (2007).
  CAS PubMed Google Scholar
• Boorjian, S. A. et al. T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. Clin. Cancer Res. 14, 4800–4808 (2008).
  CAS PubMed Google Scholar
• Tringler, B. et al. B7-H4 is highly expressed in ductal and lobular breast cancer. Clin. Cancer Res. 11, 1842–1848 (2005). Although the receptor for B7-H4 is unknown, this inhibitory B7 family member is highly expressed in breast cancer, suggesting a mechanism of immune evasion and encouraging drug development.
  CAS PubMed Google Scholar
• Krambeck, A. E. et al. B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc. Natl Acad. Sci. USA 103, 10391–10396 (2006).
  CAS PubMed PubMed Central Google Scholar
• Kryczek, I. et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J. Exp. Med. 203, 871–881 (2006).
  CAS PubMed PubMed Central Google Scholar
• Simon, I. et al. B7-H4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer. Cancer Res. 66, 1570–1575 (2006).
  CAS PubMed Google Scholar
• Tringler, B. et al. B7-H4 overexpression in ovarian tumors. Gynecol. Oncol. 100, 44–52 (2006).
  CAS PubMed Google Scholar
• Chen, L. J. et al. B7-H4 expression associates with cancer progression and predicts patient's survival in human esophageal squamous cell carcinoma. Cancer Immunol. Immunother. 60, 1047–1055 (2011).
  CAS PubMed Google Scholar
• Arigami, T. et al. Clinical significance of the B7-H4 coregulatory molecule as a novel prognostic marker in gastric cancer. World J. Surg. 35, 2051–2057 (2011).
  PubMed Google Scholar
• Jiang, J. et al. Tumor expression of B7-H4 predicts poor survival of patients suffering from gastric cancer. Cancer Immunol. Immunother. 59, 1707–1714 (2010).
  CAS PubMed Google Scholar
• Wang, Y. et al. α 1 antichymotrypsin is aberrantly expressed during melanoma progression and predicts poor survival for patients with metastatic melanoma. Pigment Cell. Melanoma Res. 23, 575–578 (2010).
  CAS PubMed Google Scholar
• Awadallah, N. S. et al. Detection of B7-H4 and p53 in pancreatic cancer: potential role as a cytological diagnostic adjunct. Pancreas 36, 200–206 (2008).
  CAS PubMed Google Scholar
• Quandt, D., Fiedler, E., Boettcher, D., Marsch, W. & Seliger, B. B7-H4 expression in human melanoma: its association with patients' survival and antitumor immune response. Clin. Cancer Res. 17, 3100–3111 (2011).
  CAS PubMed Google Scholar
• Schulkens, I. A. et al. Galectin expression profiling identifies galectin-1 and galectin-9δ5 as prognostic factors in stage I/II non-small cell lung cancer. PLoS ONE 9, e107988 (2014).
  PubMed PubMed Central Google Scholar
• Lahm, H. et al. Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures. J. Cancer Res. Clin. Oncol. 127, 375–386 (2001).
  CAS PubMed Google Scholar
• Lotan, R. et al. Lactose-binding lectin expression in human colorectal carcinomas. Relation to tumor progression. Carbohydr. Res. 213, 47–57 (1991).
  CAS PubMed Google Scholar
• Miyazaki, J. et al. Increased expression of galectin-3 in primary gastric cancer and the metastatic lymph nodes. Oncol. Rep. 9, 1307–1312 (2002).
  CAS PubMed Google Scholar
• Pallesen, G. & Hamilton-Dutoit, S. J. Ki-1 (CD30) antigen is regularly expressed by tumor cells of embryonal carcinoma. Am. J. Pathol. 133, 446–450 (1988).
  CAS PubMed PubMed Central Google Scholar
• Jilaveanu, L. B. et al. CD70 expression patterns in renal cell carcinoma. Hum. Pathol. 43, 1394–1399 (2012).
  CAS PubMed PubMed Central Google Scholar
• Yang, Z. Z., Novak, A. J., Ziesmer, S. C., Witzig, T. E. & Ansell, S. M. CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25 T cells. Blood 110, 2537–2544 (2007).
  CAS PubMed PubMed Central Google Scholar
• Schreiner, B. et al. Expression of the B7-related molecule ICOSL by human glioma cells in vitro and in vivo. Glia 44, 296–301 (2003).
  PubMed Google Scholar
• Martin-Orozco, N. et al. Melanoma cells express ICOS ligand to promote the activation and expansion of T-regulatory cells. Cancer Res. 70, 9581–9590 (2010).
  CAS PubMed PubMed Central Google Scholar
• Sloan, K. E. et al. CD155/PVR plays a key role in cell motility during tumor cell invasion and migration. BMC Cancer 4, 73 (2004).
  PubMed PubMed Central Google Scholar